• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats

    2017-02-27 05:54:23ViktoriaBekusovaVasilyPatsanovskiiAlexanderNozdrachevAlexandrTrashkovMargaritaArtemenkoVladimirAnisimovDepartmentofPhysiologyStPetersburgStateUniversityStPetersburg978RussiaPavlovInstituteofPhysiologyRussianAcademyofSciencesS
    Cancer Biology & Medicine 2017年1期

    Viktoria V. Bekusova, Vasily M. Patsanovskii, Alexander D. Nozdrachev,, Alexandr P. Trashkov, Margarita R. Artemenko, Vladimir N. AnisimovDepartment of Physiology, St. Petersburg State University, St. Petersburg 978, Russia;I.P.Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg 990, Russia;Deparment of Experimental Pharmacology, I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, The Russian Academy of Sciences, St. Petersburg 9, Russia;Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St. Petersburg 97758, Russia

    Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats

    Viktoria V. Bekusova1, Vasily M. Patsanovskii2, Alexander D. Nozdrachev1,2, Alexandr P. Trashkov3, Margarita R. Artemenko3, Vladimir N. Anisimov41Department of Physiology, St. Petersburg State University, St. Petersburg 197183, Russia;2I.P.Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg 199034, Russia;3Deparment of Experimental Pharmacology, I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, The Russian Academy of Sciences, St. Petersburg 194223, Russia;4Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St. Petersburg 197758, Russia

    Effects of two doses of the anti-diabetic drug, metformin (MF), on hormonal and metabolic levels of serum of non-diabetic male Wistar rats with 1,2-dimethylhydrazine (DMH)-induced colon tumor adenocarcinomas were studied. Carcinogenesis in the animals was also observed. Rats with DMH-induced colon adenocarcinomas had elevated levels of serum glucose, insulin, insulinlike growth factor-1, total cholesterol, triglycerides, catalase, malonic dialdehyde, glycated hemoglobin, aspartate aminotransferase, and alanine aminotransferase and decreased hemoglobin. Treatment with two doses of MF normalized majority of these changes in DMH-treated rats, whereas the drug was ineffective in rats without DMH treatment. The only exception was the decreased triglyceride levels in MF-treated rats. A 100 mg/kg dose of MF increased DMH-induced exophytic colon carcinomas and decreased endophytic tumors compared with untreated rats. Moreover, both MF doses increased DMH-induced and highly differentiated tumors and decreased the invasiveness of colon carcinomas compared with rats provided with DMH and water. Therefore, effects of MF on metabolic homeostasis are critical for preventing colon cancer.

    Colon cancer; prevention; 1,2-dimethylhydrazine; metformin; rat

    Introduction

    Colorectal cancer (CRC) is the third most common malignancy in humans worldwide; more than one million new cases occur annually1. Age is a leading CRC risk factor. More than 90% of CRC cases occur in people aged over 50, and approximately 75% of the cases are diagnosed in people older than 65. Furthermore, risks starting at 40 years of age increase sharply at 50 and double each decade until age 802. Hyperinsulinemia and obesity are key factors in cancer pathogenesis, including CRC3-6. The chemical carcinogen, 1, 2-dimethylhydrazine (DMH), has been widely used for induction of colon cancer. Regardless of mode of administration, DMH specifically induces tumors within thedescending colon of rats and some mouse strains, and resulting histopathologies are similar to those observed in human sporadic colon tumors7,8. Meanwhile, the antidiabetic biguanide, metformin (MF), lowers elevated insulin levels in type 2 diabetes3,9, significantly reduces various cancer risks in humans with the condition, and prevents tumor development in numerous rodent tissues and organs10,11. Furthermore, MF inhibits some chemically induced colon carcinogenesis in diabetic, obese12, and nondiabetic rats13. In this work, we showed the inhibitory effects of MF on DMH-induced colon carcinogenesis in nondiabetic rats. Such effects mainly involve the normalizing influence of MF on hormonal and metabolic homeostases.

    Material and methods

    Animals

    Male Wistar rats aged 2 months were bred at the Animal Laboratory of the I.P. Pavlov Institute of Physiology. Six toseven rats were kept in T3-type cages under a standard light/dark regimen (12 h light: 12 h darkness) at (22±2)°C and received standard laboratory PK-120 (Laboratorkorm, Russia)14and tap water ad libitum.

    Animals were checked daily by animal care personnel and weekly by a veterinarian. The weights were measured weekly as well. The study was conducted per the regulations for ensuring humane treatment of animals under the approval of the Committee on Animal Research of N.N. Petrov Research Institute of Oncology.

    Chemicals

    DMH was provided by Sigma Chemical Co., St. Lois, MO, USA and kept at –20°C. MF (MF HCl, Siophor) was purchased from Berlin-Chemie, Menarini Group, Germany.

    Experiment 1

    A total of 58 male Wistar rats with 2-month-old were randomly subdivided into 6 groups. A total of 24 rats in groups 1–3 were not exposed to carcinogens, whereas 34 rats from groups 4–6 were administered with 5 subcutaneous DMH injections weekly at a single dose of 21 mg/kg of body weight (calculated as a base). In this regimen, carcinogens induced colon tumors in majority of rats7. DMH was ex tempore dissolved in normal saline and neutralized with sodium bicarbonate (pH 7.0). Starting from the first carcinogen injection, groups 1 and 4 were provided with 1 mL tap water via intragastric gavage, whereas groups 2 and 5 were administered daily with MF (100 mg/kg) via gavage. Groups 3 and 6 were given MF (300 mg/kg) dissolved in 1 mL tap water. This treatment was concluded 2 months after the first DMH injection. The experiment was finalized six months after the first carcinogen injection. After being sacrificed by ether vapor, rats were decapitated, and blood samples were collected in plastic vessels without anticoagulants. After letting the samples stand for 30 min at room temperature, they were centrifuged (30 min at 1200 g) and then kept at –20°C until biochemical analyses. Metabolic parameters were assessed in blood serum. Glucose concentration was electrochemically estimated via an express analyzer (i-STAT, Abbot) that uses CG8+ cartridges. Total cholesterol, triglyceride, hemoglobin, and malonic dialdehyde (MDA) concentrations, and Cu, Zn-superoxide dismutase (SOD), catalase, alaninaminotransferase (ALT), and aspartataminotransferase (AST) activities were processed using Stat Fax 3300 analyzer and commercial reagent kits following the manufacturers’ instructions. Vascular endothelial growth factor (VEGF), insulin, and insulin-like growth factor (IGF-1) concentrations were assessed using enzyme-linked immunosorbent assay using Cusabio and R&B Systems reagent kits per standard procedures. Glycated hemoglobin was estimated using high performance liquid chromatography.

    Experiment 2

    A total of 24 male Wistar rats with 2-month-old were randomly subdivided into three groups and exposed to DMH and the same two doses of MF, as in Experiment 1. Experiment 2 was finalized six months after the first carcinogen injection. After being sacrificed using ether vapor, rats were autopsied by longitudinally opening the intestines. Tumor position and size were recorded7. After histological processing, tissues were embedded in paraffin. Histological sections measuring 3 μm thick were stained with hematoxylin-eosin and microscopically examined; in the experimental group, examination was performed as blind process. Tumors were classified per International Agency for Research on Cancer recommendations15.

    Statistical analysis

    Experimental results were statistically processed following variation statistics using Statistica-10. All data were expressed as mean ± standard error (Figures 1 and 2) or confidence interval for the standard deviation (Table 1). The significance of discrepancies was defined according to Chi-square analysis between experimental and control groups (Table 1). Differences in estimated parameters among the groups were assessed using non-parametric criterion of Mann-Whitney U test (Figures 1 and 2)16. P<0.01 and 0.05 were considered as significant.

    Results

    Effect of MF on DMF-induced hormonal and metabolic disturbances in male rats

    MF treatment failed to influence weight gain in both non-(groups 2 and 3) and DMH-exposed rats (groups 5 and 6). Thus, MF did not significantly affect weight gain between non- and DMH-exposed groups (data not shown). Twomonth administration of both doses of MF to non-exposed rats significantly decreased triglyceride serum levels and failed to influence other metabolic parameters (Figure 1). Dramatic parameter disturbances were observed in DMH and water-treated rats. The animals were sacrificed six months after the first carcinogen injection. Compared withthe control group, non-treated rats had increased levels of glucose (+25.6%), insulin (+36.2%), IGF-1 (+37.1%), total cholesterol (+47.4%), and triglycerides (+106.9%) and increased activities of catalase (+35.3%), MDA (+33.3%), AST (+93.8%), ALT (+71.4%), VEGF (+65.5%), and glycated hemoglobin (+56.7%). SOD activity did not change significantly (+19.2%, P>0.05). Both MF doses alleviated carcinogenic effects. Majority of parameters were normal, and indices covered those DMH-unexposed and MF-untreated rats (Figure 1A–1M).

    Figure 1 Effect of 1,2-dimethylhydrazine (DMH) and metformin on hormonal and metabolic parameters in the serum male Wistar rats. (A) glucose. (B) Insulin. (C) IGF-1. (D) Total cholesterol. (E) Triglycerides. (F) Cu, Zn-superoxide dismutase. (G) Catalase. (H) Malonic dialdehyde. (I) Hemoglobin. (J) Glycated hemoglobin. (K) Alaninaminetransferase. (L) Aspartataminetransferase. (M) VEGF. Data presented as mean±SEM, n=6–15 per group. P≤0.05. a: DMH vs. control; b: DMH+MF vs. DMH. Rats bearing DMH-induced colon adenocarcinomas have elevated serum level of glucose, insulin, IGF-1, total cholesterol, triglycerides, catalase, malonic dialdehyde, glycated hemoglobin, AST, ALT and decreased level of hemoglobin. Treatment with MF in both doses normalized majority of these changes in DMH-treated group of rats, whereas failed to modify them in rats not treated with DMH. Only exception was decreased level of triglycerides in MF-treated rats (Figure 1E, P<0.05).

    Table 1 Colon tumors localization, incidence, multiplicity and size in rats exposed to 1,2-dimethylhydrazine (DMH) and metformin

    Effects of MF on DMH-induced colon carcinogenesis in male rats

    In Experiment 2, intestinal tumors were found in majority of DMH-exposed rats (Table 1).

    In group 1 (DMH+water), all rats developed colon tumors (100%). Tumor incidences in different colon parts in group 1 varied: 63% in ascending colon, 100% in descending colon, and 25% in rectum. Moreover, 76.7% of colon tumors were observed in descending colons, 16.7% in ascending colons, and 6.7% in rectums. Maximal effect of 100 mg/kg daily MF dose was observed in the ascending colon, in which DMH-induced carcinogenesis was also completely inhibited (Table 1). The two MF doses did not affect colon carcinoma incidence in rat rectums and descending colons. Higher MF dose (300 mg/kg) was less effective in suppressing colon carcinogenesis compared with lower amounts (100 mg/kg).

    Macroscopically, neoplasms are exophytic or endophytic. Microscopically, malignant intestinal tumors have different types, among which tubular adenocarcinomas are predominant. All carcinoma types are typical in DMH-induced neoplasms15. Table 1 and Figure 2 present the data on the effects of MF on DMH-induced colon tumor development.

    Figure 2 Effect of metformin on some parameters of 1,2-dimethylhydrazine-induced colon carcinogenesis in male Wistar rats. Data presented as mean±SEM, n=7–9 per group. * Р<0.01; § P<0.05 vs. DMH group. Treatment with MF in dose 100 mg/kg increased relative number of induced with DMH exophytic colon carcinomas and decreased number of endophytic tumors. Both doses of MF increased relative number of DMH-induced highly differentiated tumors and decreased invasiveness of colon carcinomas as compare with group given DMH with water.

    Morphological analysis showed that tumors with exophytic growth patterns developed more frequently in the group treated with 100 mg/kg MF compared with DMH + water group. Opposite results were observed with endophytic colon tumors (Figure 2A). The group that was treated with lower MF dose had less invasive (Figure 2B) and more differentiated tumors (Figure 2C) compared with the DMH + water group. Figure 3 shows microphotographs of the observed colon adenocarcinoma types. Tumor size distribution analysis showed that in descending colons of DMH + water and DMH + MF groups, 300 small tumors (<10 mm2) appeared less frequently compared with the MF group with 100 mg/kg dose (26%, 26%, and 50%, correspondingly). Thus, these data indicate the inhibitory effects of MF on DMH-induced colon carcinogenesis.

    Discussion

    The DMH-induced carcinogenesis in epithelial cells includes the following: formation of most active metabolites (methylazoxymethanol or methyldiazohydrate) in the liver; binding of metabolites to glucuronic acid; delivery of conjugates to intestines via blood flow; release of active metabolites through enzymatic activity of intestinal flora (?glucuronidase); formation of carbonium ion (CH3+); specific methylation of macromolecules, which in enterocytes, are mainly DNA at O6position of guanine; miscoding effects7. These events result in mutation and activation of Ki-ras oncogene and inactivation of p5317. Moreover, reports presented the significant role of free radicals in DMH-induced colon carcinogenesis18,19. The present study confirmed the effects of DMH on oxidative stress parameters. Furthermore, we showed the normalizing effect of MF on MDA levels in DMH-treated rats (Figure 1). Bordini et al.20observed similar effects of MF in azoxymethane (AOM)-exposed mice. Shortly after starting DMH treatment, exposed organisms experienced significant disturbances in their neuroendocrine and immune systems and lipid and carbohydrate metabolisms. DMH treatment was followed by an increase in sensitivity threshold of the hypothalamus to inhibition by estrogen21, decrease in hypothalamic biogenic amine content22, and disturbances in diurnal rhythms at biogenic amine levels in hypothalamic nuclei of rats23. Antidiabetic biguanide treatment alleviated immunodepression in rodents exposed to DMH24and AOM25. We observed increased levels of glucose, insulin, IGF-1, total cholesterol, triglycerides, MDA, glycated hemoglobin, and VEGF in serum of rats with DMH-induced colon tumors compared with the group without DMH (Figure 1). These findingsagree with available data12,13,26,27. Furthermore, we observed the normalizing effects of both MF doses on these parameters in DMH-exposed rats (Figure 1). Notably, AST and ALT levels were not different in rats treated with higher and lower MF doses, thereby suggesting the non-toxicity of MF on liver functions.

    Figure 3 Microphotographs of 1,2-dimethylhydrazine-induced colon adenocarcinomas. (A) Highly differentiated adenocarcinoma. (B) Moderately differentiated adenocarcinoma. (C) Low differentiated adenocarcinoma (H&E stainning, 70×).

    Table 2 summarizes the data on inhibitory effects of antidiabetic biguanides on colon carcinogenesis. In most studies, anti-diabetic biguanides inhibited AOM- or DMH-induced colon carcinogenesis in mice and rats. Detailed analysis of experimental results are provided elsewhere28,29. MF treatment was followed by decreased levels of proliferation indices, which were evaluated with 5-bromodesoxyuridine, proliferating cell nuclear antigen indices, phosphorylated mechanistic target of rapamycin (mTOR), S6 kinase, and S6 proteins, as revealed by Western blot analysis, in the colonic mucosa of AOM-treated mice30. The authors believe that MF suppresses colonic epithelial proliferation by inhibiting the mTOR pathway through 5’ adenosine monophosphateactivated protein kinase activation. However, MF did not affect the level of O6-Methylguanin in the colon or liver of AOM-treated mice. Results showed that MF did not affect the AOM alkylation capacity and carcinogenicity. Therefore, the normalizing effect of MF on neuroendocrine and hormonal metabolic shifts, which occurred in rodents during colon carcinogenesis, are critical in colon cancer prevention.

    Zaafar et al.32studied the effects of MF on cancer development in diabetic and non- diabetic mice. In diabetic mice, MF treatment alone increased the number of surviving mice compared with the diabetic DMH group. Moreover, MF significantly reduced histopathological scores in diabetic mice colons. Serum VEGF levels in non-diabetic DMH group were not significantly higher than those of non-diabetic saline groups. In non-diabetic mice, MF reduced the serum concentration of VEGF compared with those in the nondiabetic/DMH control. In our study, we observed a tendency toward an increased VEGF level in DMH-treated rats compared with control animals, which were not exposed to carcinogens, whereas MF did not influence this parameter. Statistical analysis showed a significantly reduced histopathologic score for colon mucosa of MF-treated diabetic mice compared with DMH control, whereas in nondiabetic animals, the drug failed to improve the scores. This study highlighted the high susceptibility of diabetic rodents to carcinogenic effects of DMH. Inhibitory effects of MF on DMH-induced colon carcinogenesis were observed in Sprague Dawley rats with type 2 diabetes; the condition was induced with small dose of streptozotocin combined with a high-fat diet12. MF treatment was followed by decreases in ACF number, colonic tissue proliferation, and colon tumor incidence, multiplicity, and size. These results and other studies confirmed the role of diabetes as risk factor for cancer and established a connection between glucose levels and development of micro- and macro-vascular complications37,38. Our data agree with the other studies, showing that MF is effective in cancer prevention in both diabetic and non-diabetic animals that are exposed to DMH or AOM (Table 2)10,11. Moreover, clinical trials demonstrated the decrease in colon cancer risk of type 2 diabetes and non-diabetic patients39-51. Meta-analysis of 37 studiescomprising more than 1.5 million participants showed that risk of colon cancer mortality was reduced by 23% in MF users compared with non-users46. Thus, most epidemiological data and clinical trial results present sufficient evidence of MF efficacy in CRC prevention and treatment in humans. Furthermore, low daily MF dose (500 mg) was effective in reducing cancer risk in type 2 diabetes patients52. Our findings on efficacy of lower MF dose in rats agree with clinical data. Given the practical significance of these observations, future investigations are needed to elucidate the advantage of using lower doses of the drug.

    Table 2 Effect of anti-diabetic drugs on colon carcinogenesis in rodents

    Acknowledgments

    This work was supported in part by a grant from the Russian Foundation for Basic Research (Grant No. 14-04-01653). Authors are very thankful to Dr. A.V. Panchenko and Dr. M.A. Zabezhinski for help and valuable advice during the study.

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    1.Globocan 2013, Cancer Fact Sheets for Colorectal Cancer. http://globocan.iarc.fr/old/FactSheets/cancers/colorectal-new.asp.

    2.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10–29.

    3.Dilman VM. Development, Aging and Disease: A New Rationale for an Intervention. Chur: Harwood Academic Publishers; 1994.

    4.Facchini F, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001; 86: 3574–8.

    5.Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002; 11: 385–91.

    6.Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer. 2010; 17: 351–60.

    7.Pozharisski KM, Likhachev AJ, Klimashevski VF, Shaposhnikov JD. Experimental intestinal cancer research with special reference to human pathology. Adv Cancer Res. 1979; 30: 165–237.

    8.Rogers AE, Nauss KM. Rodent models for carcinoma of the colon. Dig Dis Sci. 1985; 30: 87S-102S.

    9.Shaw RJ, Lamia KA, Vasques D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310: 1642–6.

    10.Anisimov VN. Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget. 2015; 6: 39398–407.

    11.Anisimov VN. Metformin for prevention and treatment of colon cancer: a reappraisal of experimental and clinical data. Current Drug Target. 2016; 17: 439–46.

    12.Jia YL, Ma ZY, Liu XF, Zhou WJ, He S, Xu X, et al. Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the Warburg effect. Cancer Med. 2015; 4: 1730–41.

    13.Li W, Wang QL, Liu X, Dong SH, Li HX, Li CY, et al. Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res. 2015; 8: 139–48.

    14.Anisimov VN, Popovich IG, Zabezhinski MA. Methods of testing pharmacological drugs effects on aging and life span in mice. In: Tollefsbol TO, editor. Biological Aging: Methods and Protocols. 2nd ed. New York: Humana Press; 2013. p.145–60.

    15.Turusov VS. Pathology of Tumours in Laboratory Animals, Vol. 1: Tumours of the Rat. 2nd ed. Lyon: International Agency for Research on Cancer; 1990.

    16.Goubler EV. Calculation Methods in Analysis and Identification of Pathological Processes. Moscow: Meditsina; 1978.

    17.Zusman I. The role of p53 tumor-associated protein in colon cancer detection and prevention (Review). Int J Oncol. 1997; 10: 1241–9.

    18.Salim AS. The permissive role of oxygen-derived free radicals in the development of colonic cancer in the rat. A new theory for carcinogenesis. Int J Cancer. 1993; 53: 1031–5.

    19.Arutiunian AV, Prokopenko VM, Burmistrov SO, Oparina TI, Frolova EV, Zabezhinsk? MA, et al. Free-radical processes in blood serum, liver and large bowel during 1,2-dimethylhydrazine-induced carcinogenesis in rats. Vopr Onkol. 1997; 43: 618–22.

    20.Bordini HP, Kremer JL, Fagundes TR, Melo GP, Conchon-Costa I, da Silva SS, et al. Protective effect of metformin in an aberrant crypt foci model induced by 1, 2-dimethylhydrazine: Modulation of oxidative stress and inflammatory process. Mol Carcinog. 2016. DOI: 10.1002/mc.22545.

    21.Pozharisski K, Anisimov V. On the role of endocrine system in development of experimental colon tumors in rats. Pathol Physiol. 1975; 1: 47–50.

    22.Anisimov VN, Pozdeev VK, Dmitrievskaia A, Gracheva GM, Il’in AP. Effect of enterotropic carcinogen 1, 2-dimethylhydrazine on the level of biogenic amines in the hypothalamus of rats. Bull Eksp Biol Med. 1976; 82: 1359–61.

    23.Arutjunyan AV, Kerkeshko GO, Anisimov VN, Stepanov MG, Prokopenko VM, Pozdeyev NV, et al. Disturbances of diurnal rhythms of biogenic amines contents in hypothalamic nuclei as an evidence of neurotropic effects of enterotropic carcinogen 1, 2-dimethylhydrazine. Neuro Endocrinol Lett. 2001; 22: 229–37.

    24.Dil’man VM, Sofronov BN, Anisimov VN, Nazarov PG, L’vovich EG. Phenformin elimination of the immunodepression caused by 1, 2-dimethylhydrazine in rats. Vopr Onkol. 1977; 23: 50–4.

    25.Chung EJ, Do EJ, Kim SY, Cho EA, Kim DH, Pak S, et al. Combination of metformin and VSL#3 additively suppresses western-style diet induced colon cancer in mice. Eur J Pharmacol.2017; 794: 1–7.

    26.Dubina MV, Petrishchev NN, Anisimov VN. Microvascular endothelium dysfunction in rats bearing 1, 2-dimethylhydrazineinduced colon tumors. Cancer Lett. 1999; 144: 125–9.

    27.Shimomoto T, Luo Y, Ohmori H, Chihara Y, Fujii K, Sasahira T, et al. Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. J Gastroenterol. 2012; 47: 1073–83.

    28.Anisimov VN. Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Trans Med. 2014; 2: 60.

    29.Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY). 2010; 2: 760-74.

    30.Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010; 49: 662–71.

    31.Abdulkareem HA, Hussein AG, Mahmood AS. Efficacy of intraperitoneal administration of metformin and 5-fluoruracil in prevention of induced-colorectal aberrant crypt foci in mice. Int J Pharmacy Pharmaceut Sci. 2014; 6: 305–8.

    32.Zaafar DK, Zaitone SA, Moustafa YM. Role of metformin in suppressing 1, 2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation: PLoS One. 2014; 9: e100562.

    33.Rao CV, Janakiram NB, Mohammed A, Madka V, Qian L, Brewer M, et al. Lack of chemopreventive effects of metformin in azoxymethane-induced rat colon carcinogenesis. Cancer Prev Res. 2011; 4: B42.

    34.Madka V, Zhang Y, Brewer M, Rao C, Janakiram N, Mohammed A, et al. Chemopreventive efficacy of bisphosphonates, Zometa and Fosamax, alone or in combination with metformin in AOM-induced rat colon cancer model. Cancer Prev Res. 2013; 6: A14.

    35.Anisimov VN, Pozharisski? KM, Dil’man VM. Effect of phenformin on the blastomogenic action of 1, 2-dimethylhydrazine in rats. Vopr Onkol. 1980; 26: 54–8.

    36.Popovich IG, Zabezhinski MA, Egormin PA, Tyndyk ML, Anikin IV, Spasov AA, et al. Insulin in aging and cancer: antidiabetic drug diabenol as geroprotector and anticarcinogen. Int J Biochem Cell Biol. 2005; 37: 1117–29.

    37.Markowitz SD, Bertagnolli MM. Molecular basis for colorectal cancer. N Engl J Med. 2009; 361: 2449–60.

    38.Feng YH, Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, et al. microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med. 2012; 29: 920–6.

    39.Zhang PP, Li H, Tan XH, Chen LL, Wang SM. Association of metformin use with cancer incidence and mortality: A metaanalysis. Cancer Epidemiol. 2013; 37: 207–18.

    40.Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res. 2010; 3: 1077–83.

    41.Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012; 12: 118.

    42.Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One. 2014; 9: e91818.

    43.Cardel M, Jensen SM, Potteg?rd A, J?rgensen TL, Hallas J. Longterm use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. Cancer Med. 2014; 3: 1458–66.

    44.Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012; 29: 1314–27.

    45.Nangia-Makker P, Yu YJ, Vasudevan A, Farhana L, Rajendra SG, Levi E, et al. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One. 2014; 9: e84369.

    46.Zhang YF, Guan MP, Zheng ZJ, Zhang Q, Gao F, Xue YM. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One. 2013; 8: e81264.

    47.Zhang ZJ, Zheng ZJ, Kan HD, Song YQ, Cui W, Zhao GM, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34: 2323–8.

    48.Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766–77.

    49.Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist. 2013; 18: 1248–55.

    50.Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1877–83.

    51.Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016; 17: 475–83.

    52.Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang HY, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer. 2011, 11: 20.

    Cite this article as:Bekusova VV, Patsanovskii VM, Nozdrachev AD, Trashkov AP, Artemenko MR, Anisimov VN, et al. Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats. Cancer Biol Med. 2017; 14: 100-7. doi: 10.20892/j.issn.2095-3941.2016.0088

    Viktoria V. Bekusova

    E-mail: v.bekusova@spbu.ru

    Received October 26, 2016; accepted November 28, 2016. Available at www.cancerbiomed.org

    Copyright ? 2017 by Cancer Biology & Medicine

    欧美+日韩+精品| 黑人高潮一二区| 久久久久免费精品人妻一区二区| 久久久久国产网址| 99视频精品全部免费 在线| 国产成人a区在线观看| 日韩视频在线欧美| 欧美一级a爱片免费观看看| 久久精品熟女亚洲av麻豆精品 | 精品一区二区三卡| 波多野结衣巨乳人妻| 亚洲精品一二三| 久久久久国产网址| 午夜福利在线观看免费完整高清在| 22中文网久久字幕| 免费高清在线观看视频在线观看| 亚洲自拍偷在线| 草草在线视频免费看| 我的女老师完整版在线观看| 日本免费a在线| 国产亚洲精品久久久com| 亚洲美女搞黄在线观看| 九草在线视频观看| 热99在线观看视频| 观看美女的网站| 免费在线观看成人毛片| 午夜免费观看性视频| 亚洲av日韩在线播放| 国产一区亚洲一区在线观看| 能在线免费看毛片的网站| 欧美成人午夜免费资源| 国产老妇女一区| 亚洲av成人精品一二三区| 欧美zozozo另类| 亚洲精品中文字幕在线视频 | 国产成年人精品一区二区| 久久午夜福利片| 精品久久久久久成人av| 在线a可以看的网站| 黄片wwwwww| av在线播放精品| 欧美日韩亚洲高清精品| 一个人看视频在线观看www免费| 汤姆久久久久久久影院中文字幕 | 亚洲在线自拍视频| 午夜福利网站1000一区二区三区| 精品久久国产蜜桃| 麻豆精品久久久久久蜜桃| 精品久久久久久久人妻蜜臀av| 亚洲精品aⅴ在线观看| av又黄又爽大尺度在线免费看| 欧美日韩国产mv在线观看视频 | 中文字幕亚洲精品专区| 亚洲成色77777| 激情 狠狠 欧美| 亚洲综合精品二区| 国产成人a区在线观看| 日本-黄色视频高清免费观看| 国产精品国产三级国产av玫瑰| 亚洲综合精品二区| a级一级毛片免费在线观看| 国内少妇人妻偷人精品xxx网站| 午夜激情久久久久久久| 99热6这里只有精品| 成人午夜精彩视频在线观看| 国产黄色免费在线视频| 女人十人毛片免费观看3o分钟| 久久99热6这里只有精品| 国产精品人妻久久久久久| 亚洲精品自拍成人| 日本av手机在线免费观看| 91精品国产九色| 亚洲欧美日韩东京热| 亚洲成人中文字幕在线播放| 国产免费视频播放在线视频 | 国产精品久久久久久精品电影| 成人午夜高清在线视频| 高清在线视频一区二区三区| 国产高潮美女av| 高清av免费在线| 最近2019中文字幕mv第一页| 欧美人与善性xxx| 婷婷色综合大香蕉| 成人午夜高清在线视频| 老女人水多毛片| 在线a可以看的网站| 丰满人妻一区二区三区视频av| 高清欧美精品videossex| 日日啪夜夜爽| 成人毛片60女人毛片免费| 又粗又硬又长又爽又黄的视频| 亚洲四区av| 亚洲在线自拍视频| 国产av在哪里看| 一个人免费在线观看电影| 国产精品国产三级国产专区5o| 日韩在线高清观看一区二区三区| av国产免费在线观看| 搡老妇女老女人老熟妇| 午夜久久久久精精品| 全区人妻精品视频| 免费不卡的大黄色大毛片视频在线观看 | 日韩三级伦理在线观看| 亚洲精品乱久久久久久| 日韩国内少妇激情av| 久久久久免费精品人妻一区二区| 欧美精品一区二区大全| 最新中文字幕久久久久| 少妇丰满av| 91久久精品国产一区二区三区| 久久精品夜夜夜夜夜久久蜜豆| 亚洲欧洲国产日韩| 精品久久国产蜜桃| 久久综合国产亚洲精品| 欧美成人一区二区免费高清观看| 久久精品夜色国产| 国产亚洲av片在线观看秒播厂 | 欧美日韩综合久久久久久| 黄片无遮挡物在线观看| 午夜激情久久久久久久| 天天躁日日操中文字幕| 麻豆精品久久久久久蜜桃| 中文字幕久久专区| 欧美激情久久久久久爽电影| 我的女老师完整版在线观看| 韩国高清视频一区二区三区| 国产精品一区二区在线观看99 | 内地一区二区视频在线| 夜夜看夜夜爽夜夜摸| 中文精品一卡2卡3卡4更新| 水蜜桃什么品种好| 国产精品99久久久久久久久| 我的女老师完整版在线观看| 国产麻豆成人av免费视频| 日韩成人伦理影院| 国产一区二区在线观看日韩| 亚洲欧美中文字幕日韩二区| 久久久久国产网址| 国产黄a三级三级三级人| 日本黄色片子视频| 熟女电影av网| 久久久精品欧美日韩精品| 婷婷色av中文字幕| 永久网站在线| 嫩草影院精品99| 国产精品伦人一区二区| 精品熟女少妇av免费看| av在线天堂中文字幕| 特大巨黑吊av在线直播| 成人毛片a级毛片在线播放| 久久久精品欧美日韩精品| 亚洲av电影不卡..在线观看| 永久网站在线| 18禁在线播放成人免费| 国产 一区 欧美 日韩| 国产精品一区二区性色av| 国国产精品蜜臀av免费| 亚洲久久久久久中文字幕| 全区人妻精品视频| 在线观看美女被高潮喷水网站| 精品99又大又爽又粗少妇毛片| 插逼视频在线观看| 深爱激情五月婷婷| 国产一区有黄有色的免费视频 | 国内精品宾馆在线| 内射极品少妇av片p| 婷婷六月久久综合丁香| 乱系列少妇在线播放| 日韩国内少妇激情av| 国产精品国产三级国产av玫瑰| 51国产日韩欧美| 不卡视频在线观看欧美| 亚洲国产欧美人成| 丝瓜视频免费看黄片| 国产精品综合久久久久久久免费| 卡戴珊不雅视频在线播放| 十八禁国产超污无遮挡网站| 日韩中字成人| 51国产日韩欧美| 99久久九九国产精品国产免费| 最近最新中文字幕免费大全7| 三级毛片av免费| 岛国毛片在线播放| 国产黄a三级三级三级人| 极品教师在线视频| av在线蜜桃| 偷拍熟女少妇极品色| 极品少妇高潮喷水抽搐| 精品不卡国产一区二区三区| 天堂√8在线中文| 国产69精品久久久久777片| 人人妻人人澡人人爽人人夜夜 | 乱码一卡2卡4卡精品| 天天躁夜夜躁狠狠久久av| 免费观看无遮挡的男女| 91精品一卡2卡3卡4卡| 亚洲国产av新网站| 亚洲精品中文字幕在线视频 | 精品久久久久久久末码| 亚洲国产日韩欧美精品在线观看| 又粗又硬又长又爽又黄的视频| 久久草成人影院| 永久网站在线| 18禁在线无遮挡免费观看视频| 大又大粗又爽又黄少妇毛片口| 国产 一区精品| 春色校园在线视频观看| 国产精品.久久久| 有码 亚洲区| 如何舔出高潮| 91久久精品电影网| 99九九线精品视频在线观看视频| 又爽又黄a免费视频| 黄色一级大片看看| 欧美精品国产亚洲| 免费黄色在线免费观看| 国产午夜精品论理片| 日韩精品有码人妻一区| 国产精品国产三级国产专区5o| 在线天堂最新版资源| 激情 狠狠 欧美| 乱码一卡2卡4卡精品| 国产精品福利在线免费观看| 日韩 亚洲 欧美在线| av福利片在线观看| 一区二区三区四区激情视频| 小蜜桃在线观看免费完整版高清| 亚洲伊人久久精品综合| 一级av片app| 国产高潮美女av| 91精品伊人久久大香线蕉| 秋霞伦理黄片| 一级毛片 在线播放| 免费看av在线观看网站| freevideosex欧美| 国语对白做爰xxxⅹ性视频网站| kizo精华| 一边亲一边摸免费视频| 精品亚洲乱码少妇综合久久| 97人妻精品一区二区三区麻豆| 亚洲国产精品成人久久小说| 国产av码专区亚洲av| 青青草视频在线视频观看| av在线老鸭窝| 搡女人真爽免费视频火全软件| 日韩 亚洲 欧美在线| 三级男女做爰猛烈吃奶摸视频| 美女xxoo啪啪120秒动态图| 在线观看人妻少妇| 国内揄拍国产精品人妻在线| 久久精品久久久久久久性| av在线蜜桃| 18禁在线无遮挡免费观看视频| 亚洲无线观看免费| 一级毛片电影观看| 大又大粗又爽又黄少妇毛片口| 久久精品夜夜夜夜夜久久蜜豆| 久久人人爽人人片av| 一级毛片黄色毛片免费观看视频| 久久6这里有精品| 日韩一区二区视频免费看| 久久这里只有精品中国| 成人亚洲精品av一区二区| 亚洲av国产av综合av卡| 国产精品一区www在线观看| 成年版毛片免费区| 18禁在线播放成人免费| 国产精品人妻久久久久久| av又黄又爽大尺度在线免费看| 国产91av在线免费观看| 日韩欧美精品v在线| 久久久久网色| 国产老妇女一区| 国产精品女同一区二区软件| 久久精品国产亚洲av天美| 国产爱豆传媒在线观看| 亚洲av免费高清在线观看| 国产一区二区三区综合在线观看 | 国产成人精品婷婷| 亚洲av在线观看美女高潮| 中文欧美无线码| 水蜜桃什么品种好| 男的添女的下面高潮视频| 久久久久九九精品影院| 色网站视频免费| 乱人视频在线观看| 亚洲精品一二三| 国产av不卡久久| 狠狠精品人妻久久久久久综合| 久久99精品国语久久久| 国产精品久久久久久精品电影小说 | 成年免费大片在线观看| 免费观看在线日韩| 午夜免费激情av| 久久亚洲国产成人精品v| 午夜激情久久久久久久| 十八禁国产超污无遮挡网站| 国产精品国产三级国产av玫瑰| 亚洲精品国产av蜜桃| 街头女战士在线观看网站| 国产精品久久久久久精品电影小说 | 欧美日韩亚洲高清精品| 亚洲熟女精品中文字幕| 天堂俺去俺来也www色官网 | 午夜福利视频精品| 亚洲在线自拍视频| 91aial.com中文字幕在线观看| 最新中文字幕久久久久| 色哟哟·www| 欧美成人一区二区免费高清观看| 国产一区有黄有色的免费视频 | 美女国产视频在线观看| 麻豆成人午夜福利视频| 天天一区二区日本电影三级| 日日撸夜夜添| 熟女人妻精品中文字幕| 亚洲欧美日韩东京热| 在线免费观看的www视频| 亚洲精品成人av观看孕妇| 国产精品一区二区三区四区免费观看| 亚洲国产精品专区欧美| 日韩亚洲欧美综合| 人人妻人人看人人澡| 男女下面进入的视频免费午夜| 亚洲va在线va天堂va国产| 日韩视频在线欧美| 午夜日本视频在线| 日韩成人av中文字幕在线观看| 高清在线视频一区二区三区| 边亲边吃奶的免费视频| 免费大片18禁| 色尼玛亚洲综合影院| 国产女主播在线喷水免费视频网站 | 亚洲欧美中文字幕日韩二区| 天天一区二区日本电影三级| 亚洲国产欧美在线一区| 免费看av在线观看网站| 亚洲久久久久久中文字幕| 高清午夜精品一区二区三区| 亚洲精品国产成人久久av| 18禁动态无遮挡网站| 亚洲成色77777| 91久久精品国产一区二区三区| av线在线观看网站| 国产永久视频网站| 欧美激情在线99| 成人一区二区视频在线观看| 亚洲av中文av极速乱| 听说在线观看完整版免费高清| 日日干狠狠操夜夜爽| 国产亚洲av片在线观看秒播厂 | 超碰av人人做人人爽久久| 午夜精品一区二区三区免费看| 婷婷色综合大香蕉| 三级国产精品片| 成年女人看的毛片在线观看| 久久97久久精品| 成人二区视频| 国产免费一级a男人的天堂| 卡戴珊不雅视频在线播放| 国产亚洲精品av在线| 国产成人91sexporn| 国产亚洲一区二区精品| 亚洲欧美一区二区三区黑人 | 午夜爱爱视频在线播放| 少妇熟女aⅴ在线视频| 一级毛片电影观看| 夜夜爽夜夜爽视频| 久久久久久九九精品二区国产| 看非洲黑人一级黄片| 嫩草影院精品99| 男人爽女人下面视频在线观看| 99久久九九国产精品国产免费| 偷拍熟女少妇极品色| 免费人成在线观看视频色| 久久久成人免费电影| 久久99热6这里只有精品| 身体一侧抽搐| 午夜福利视频精品| 80岁老熟妇乱子伦牲交| 99久久中文字幕三级久久日本| 久久精品国产亚洲网站| 99视频精品全部免费 在线| 卡戴珊不雅视频在线播放| 亚洲最大成人中文| 激情 狠狠 欧美| 国产色婷婷99| 国产成人91sexporn| 一级av片app| 免费高清在线观看视频在线观看| 日韩亚洲欧美综合| 日韩国内少妇激情av| 欧美另类一区| 国产成人精品一,二区| av播播在线观看一区| 97热精品久久久久久| 精品少妇黑人巨大在线播放| 久久久精品94久久精品| 日韩视频在线欧美| 丰满人妻一区二区三区视频av| 免费黄网站久久成人精品| 一区二区三区高清视频在线| 天美传媒精品一区二区| 天堂网av新在线| 国产不卡一卡二| 一级黄片播放器| 色网站视频免费| 国产黄片视频在线免费观看| 欧美性感艳星| 啦啦啦中文免费视频观看日本| 国产精品蜜桃在线观看| 成人亚洲精品一区在线观看 | 欧美一区二区亚洲| 观看免费一级毛片| 亚洲av成人精品一二三区| 久热久热在线精品观看| 国产av在哪里看| 国产精品久久久久久精品电影小说 | 性插视频无遮挡在线免费观看| 国产成人一区二区在线| 中文精品一卡2卡3卡4更新| 国产乱来视频区| 久久久a久久爽久久v久久| 久久99蜜桃精品久久| 大香蕉97超碰在线| 99re6热这里在线精品视频| 人妻夜夜爽99麻豆av| 婷婷色麻豆天堂久久| 国产精品久久久久久av不卡| 中国美白少妇内射xxxbb| 天堂√8在线中文| 亚洲国产精品国产精品| 男人舔女人下体高潮全视频| 色视频www国产| 国产永久视频网站| 亚洲国产精品成人久久小说| 成年女人看的毛片在线观看| 一区二区三区免费毛片| 国产成人freesex在线| 噜噜噜噜噜久久久久久91| 久久这里有精品视频免费| 亚州av有码| 亚洲美女搞黄在线观看| 免费观看a级毛片全部| 日本黄色片子视频| 自拍偷自拍亚洲精品老妇| 国产高清有码在线观看视频| 国产乱人偷精品视频| 五月伊人婷婷丁香| 麻豆乱淫一区二区| 午夜福利高清视频| 性色avwww在线观看| 国产毛片a区久久久久| 我要看日韩黄色一级片| 可以在线观看毛片的网站| 国产成人免费观看mmmm| 熟妇人妻不卡中文字幕| 91av网一区二区| 最近的中文字幕免费完整| 肉色欧美久久久久久久蜜桃 | 久久久久久久午夜电影| 黄色欧美视频在线观看| 亚洲一级一片aⅴ在线观看| 亚洲精品乱码久久久v下载方式| av免费观看日本| 美女高潮的动态| 国产av在哪里看| 人妻系列 视频| 国产黄频视频在线观看| 免费看av在线观看网站| 人人妻人人澡欧美一区二区| 三级国产精品片| 亚洲乱码一区二区免费版| 男人爽女人下面视频在线观看| 国产免费一级a男人的天堂| 好男人在线观看高清免费视频| 麻豆久久精品国产亚洲av| 成年人午夜在线观看视频 | 日韩大片免费观看网站| 直男gayav资源| 亚洲成人中文字幕在线播放| 精品欧美国产一区二区三| 国产精品1区2区在线观看.| 久久精品久久久久久噜噜老黄| 69av精品久久久久久| 少妇熟女aⅴ在线视频| 一夜夜www| 亚洲av中文字字幕乱码综合| 国产欧美另类精品又又久久亚洲欧美| 国产精品伦人一区二区| 亚洲精品日韩av片在线观看| 久久人人爽人人片av| 国内少妇人妻偷人精品xxx网站| 久久久久网色| 日韩av不卡免费在线播放| 日韩亚洲欧美综合| 中文天堂在线官网| 97精品久久久久久久久久精品| 久久热精品热| 国产精品美女特级片免费视频播放器| 国产乱人视频| 日韩亚洲欧美综合| 午夜福利高清视频| 久99久视频精品免费| 日韩欧美 国产精品| 亚洲成人久久爱视频| 国产视频内射| 久久久精品免费免费高清| 有码 亚洲区| 亚洲丝袜综合中文字幕| 一级片'在线观看视频| 久久久a久久爽久久v久久| 国产欧美另类精品又又久久亚洲欧美| 亚洲天堂国产精品一区在线| 九九久久精品国产亚洲av麻豆| 日本一本二区三区精品| 亚洲内射少妇av| 秋霞伦理黄片| 久久久精品94久久精品| 少妇的逼水好多| a级毛片免费高清观看在线播放| 日韩成人伦理影院| 久久综合国产亚洲精品| av在线亚洲专区| 日本免费a在线| 伦精品一区二区三区| 成人午夜高清在线视频| 网址你懂的国产日韩在线| 亚洲va在线va天堂va国产| 一个人看的www免费观看视频| 男女视频在线观看网站免费| 伊人久久精品亚洲午夜| 一个人免费在线观看电影| 亚洲最大成人中文| 成人特级av手机在线观看| 99久久精品一区二区三区| 亚洲熟妇中文字幕五十中出| 日韩电影二区| 搡老乐熟女国产| 久久久精品免费免费高清| 深爱激情五月婷婷| 日本熟妇午夜| av一本久久久久| 高清视频免费观看一区二区 | 国产精品一二三区在线看| 亚洲精品亚洲一区二区| 亚洲国产最新在线播放| 日韩国内少妇激情av| 卡戴珊不雅视频在线播放| 国产黄片美女视频| 欧美日韩视频高清一区二区三区二| 亚洲精华国产精华液的使用体验| 国产成人福利小说| 18禁动态无遮挡网站| 永久免费av网站大全| 最近2019中文字幕mv第一页| 成人毛片a级毛片在线播放| 午夜免费激情av| 少妇熟女aⅴ在线视频| 一个人观看的视频www高清免费观看| 成人一区二区视频在线观看| 亚洲国产欧美在线一区| 大又大粗又爽又黄少妇毛片口| 99久久精品热视频| 蜜桃久久精品国产亚洲av| 婷婷色综合大香蕉| 建设人人有责人人尽责人人享有的 | 久久久午夜欧美精品| 国产视频内射| 91av网一区二区| 国产精品久久久久久久久免| 亚洲av国产av综合av卡| 中文字幕亚洲精品专区| 亚洲国产精品专区欧美| 亚洲精品一区蜜桃| 国产 亚洲一区二区三区 | 成人亚洲精品av一区二区| 七月丁香在线播放| 日韩欧美国产在线观看| 国产精品国产三级国产av玫瑰| 精品亚洲乱码少妇综合久久| 免费不卡的大黄色大毛片视频在线观看 | 亚洲精品一二三| 国产精品国产三级国产av玫瑰| 日韩一区二区视频免费看| 欧美日韩视频高清一区二区三区二| 日本熟妇午夜| 青春草亚洲视频在线观看| 亚洲欧美日韩东京热| 久久久久九九精品影院| 91久久精品电影网| 亚洲精品中文字幕在线视频 | 日韩一区二区三区影片| 男人舔女人下体高潮全视频| 亚洲人成网站高清观看| 国产视频首页在线观看| 国产精品99久久久久久久久| 欧美xxxx黑人xx丫x性爽| 天天躁夜夜躁狠狠久久av| 特大巨黑吊av在线直播| 亚洲av免费在线观看| 欧美高清成人免费视频www| av在线播放精品| 免费观看在线日韩| 国产淫片久久久久久久久| 欧美日韩在线观看h| 十八禁国产超污无遮挡网站| 中国国产av一级| 一个人看视频在线观看www免费| 毛片女人毛片| 国产真实伦视频高清在线观看| 亚洲天堂国产精品一区在线| 国产精品日韩av在线免费观看| 一个人看视频在线观看www免费| 一二三四中文在线观看免费高清|